Sahay Bikash, Ge Yong, Colliou Natacha, Zadeh Mojgan, Weiner Chelsea, Mila Ashley, Owen Jennifer L, Mohamadzadeh Mansour
a Department of Infectious Diseases and Pathology ; University of Florida ; Gainesville , FL USA.
b Division of Hepatology, Gastroenterology, and Nutrition; University of Florida ; Gainesville , FL USA.
Gut Microbes. 2015;6(6):392-7. doi: 10.1080/19490976.2015.1107697.
Intestinal immunity is subject to complex and fine-tuned regulation dictated by interactions of the resident microbial community and their gene products with host innate cells. Deterioration of this delicate process may result in devastating autoinflammatory diseases, including inflammatory bowel disease (IBD), which primarily comprises Crohn's disease (CD) and ulcerative colitis (UC). Efficacious interventions to regulate proinflammatory signals, which play critical roles in IBD, require further scientific investigation. We recently demonstrated that rebalancing intestinal immunity via the surface layer protein A (SlpA) from Lactobacillus acidophilus NCFM potentially represents a feasible therapeutic approach to restore intestinal homeostasis. To expand on these findings, we established a new method of purifying bacterial SlpA, a new SlpA-specific monoclonal antibody, and found no SlpA-associated toxicity in mice. Thus, these data may assist in our efforts to determine the immune regulatory efficacy of SlpA in humans.
肠道免疫受到复杂且精细调节，这种调节由常驻微生物群落及其基因产物与宿主固有细胞之间的相互作用所决定。这一微妙过程的恶化可能导致毁灭性的自身炎症性疾病，包括炎症性肠病（IBD），其主要由克罗恩病（CD）和溃疡性结肠炎（UC）组成。调节在IBD中起关键作用的促炎信号的有效干预措施需要进一步的科学研究。我们最近证明，通过嗜酸乳杆菌NCFM的表层蛋白A（SlpA）来重新平衡肠道免疫，可能是恢复肠道内环境稳定的一种可行治疗方法。为了进一步拓展这些发现，我们建立了一种纯化细菌SlpA的新方法、一种新的SlpA特异性单克隆抗体，并发现小鼠中不存在与SlpA相关的毒性。因此，这些数据可能有助于我们确定SlpA在人体中的免疫调节功效。
